PALADIN (00495) announced its interim results with a shareholder loss of HK$18.553 million, a decrease of 40.7% compared to the same period last year.

17:46 27/02/2026

PALADIN (00495) announced its interim performance for the six months ended on December 31, 2025. The group achieved a profit of HK$14.917 million, representing a decrease of 29.42% compared to the same period last year. The loss attributable to shareholders for the period was HK$18.553 million, a decrease of 40.7% year-on-year, with a basic loss per share of 1.13 HK cents.

PALADIN (00495) announced its interim performance for the six-month period ending December 31, 2025. The group achieved a profit of HK$14.917 million, a decrease of 29.42% year-on-year; the company's attributable loss for the period was HK$18.553 million, a decrease of 40.7%; and basic loss per share was 1.13 HK cents. The announcement stated that the decrease in loss was mainly due to a reduction of approximately HK$17 million in fair value loss on investment properties for the six months ending December 31, 2025.

UNIVERSE ENT (01046) announced its interim financial results. The company's attributable loss was HKD 9.882 million, a year-on-year decrease of 86.7%.

REMEGEN (09995) released its annual performance, with shareholders' net profit reaching 709 million yuan, turning losses into gains compared to the previous year.

CITIC (00267): CITIC Offshore Helicopter nominates Li Gang and others as candidates for non-independent directors.

UNIVERSE ENT (01046) announced its interim financial results. The company's attributable loss was HKD 9.882 million, a year-on-year decrease of 86.7%.

REMEGEN (09995) released its annual performance, with shareholders' net profit reaching 709 million yuan, turning losses into gains compared to the previous year.

CITIC (00267): CITIC Offshore Helicopter nominates Li Gang and others as candidates for non-independent directors.